Core Insights - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases [3][4] - The company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, featuring CEO JD Finley and CMO Dr. Mitchell Jones [1][2] Company Overview - Palisade Bio is dedicated to improving pharmacology, tolerability, and convenience for patients suffering from chronic inflammatory and fibrotic diseases through its differentiated prodrug platform and precision pharmacology strategy [3] - The lead program, PALI-2108, is being developed for moderate-to-severe Ulcerative Colitis (UC) and Fibrostenotic Crohn's Disease (FSCD), addressing the need for non-immunosuppressive therapy options [4] Clinical Development - In a Phase 1b trial, PALI-2108 demonstrated a 100% clinical response in the UC cohort, with no serious adverse events and favorable tolerability [4] - The company is advancing towards a Phase 2 clinical study in UC to evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, with plans for an extension phase [5] - Additionally, studies in FSCD are being prepared to further assess PALI-2108's safety, pharmacology, and therapeutic benefits across inflammatory bowel disease indications [5]

Wilmington, NC, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Off The Hook YS Inc. (NYSE American: OTH) has confirmed the development of a new office location in Jupiter, Florida. The facility will serve as the headquarters for Autograph Yacht Group (AYG), a recently established luxury brokerage division led by industry veteran Mike Burke. In addition to housing members of Off The Hook’s C-level leadership team based in Florida, the site will strengthen the company’s footprint in one of the nation's most active yachtin ...

Core Insights - Helport AI Limited has successfully completed the 2025 AI Entrepreneurship Competition in collaboration with the University of Massachusetts Lowell, aimed at enhancing students' exposure to real-world AI applications and reinforcing the company's commitment to developing future AI talent [3][4]. Company Initiatives - The competition provided students with hands-on experience in designing and deploying enterprise-grade AI solutions, focusing on business modeling, entrepreneurial leadership, and technology commercialization [4][5]. - Students received technical training and product guidance from Helport AI, transforming their business concepts into functional prototypes, which were showcased to a panel of experts [5][6]. Strategic Goals - Helport AI aims to cultivate a next-generation AI ecosystem through university partnerships, enhancing its technical offerings and fostering talent to sustain its innovation pipeline [9][12]. - Future actions include expanding partnerships with academic institutions across U.S. campuses and launching additional AI product competitions at other colleges [10][13].

Core Viewpoint - Lakeland Industries, Inc. will host a conference call on December 9, 2025, to discuss its financial results for the fiscal third quarter of 2026, which ended on October 31, 2025 [1]. Group 1: Conference Call Details - The conference call is scheduled for December 9, 2025, at 4:30 p.m. Eastern Time [2]. - Participants can access the call via a dial-in number or through a webcast link provided [2]. - A telephone replay of the call will be available for three months after the event [2]. Group 2: Company Overview - Lakeland Fire + Safety manufactures protective clothing and accessories for various industries, including healthcare and first responders [3]. - The company sells its products globally through in-house sales teams and authorized independent sales representatives [3]. - Key markets served include oil, chemical, automotive, construction, and governmental agencies, with international sales to over 50 countries [3].

Core Insights - PodcastOne has secured a multi-year agreement with Clint Frazier for the exclusive distribution rights to his podcast "Life After the Show," marking the 19th addition to its network in 2025, bringing the total to 211 podcasts [1][6] Company Overview - PodcastOne is a leading podcast platform that offers a comprehensive solution in sales, marketing, public relations, production, and distribution, boasting over 3.9 billion total downloads and a community of 200 top podcasters [6] - The platform reaches over 1 billion monthly impressions across various channels, including YouTube, Spotify, Apple Podcasts, and iHeartRadio [6] Podcast Content - "Life After the Show" features weekly episodes where Frazier discusses current baseball issues, interviews former teammates and insiders, and shares his personal experiences post-major league career [2][4] - The podcast aims to provide unfiltered stories and insights from Frazier's time with the New York Yankees and his views on contemporary sports [2][3] Strategic Alignment - The partnership with Frazier aligns with PodcastOne's growth strategy to deliver authentic narratives from real individuals, enhancing its content diversity and listener engagement [3]

Core Insights - Integra LifeSciences Holdings Corporation commends the Centers for Medicare & Medicaid Services (CMS) for its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules, which include all of Integra's dermal regenerative templates, decellularized dermal scaffolds, and amniotic tissue membranes classified as skin substitutes [1][2] Group 1: Company Overview - Integra LifeSciences is a global medical technology leader focused on restoring lives through innovation in neurosurgery and tissue reconstruction, with a portfolio of differentiated technologies trusted by healthcare professionals [3] - The company offers a diverse range of products, including Integra matrices, PriMatrix, Cytal, and AmnioExcel, utilizing four unique technology platforms for complex wound reconstruction cases [1][3] Group 2: Industry Impact - The new CMS ruling is seen as a pivotal advancement for the industry, allowing for uniform reimbursement rates across care settings, which will expand access to Integra's product portfolio [2] - The company believes that the new policy will reward innovation, quality, and patient outcomes, areas where it has consistently led [2]

SINGAPORE, Nov. 25, 2025 (GLOBE NEWSWIRE) -- GCL Global Holdings Ltd (Nasdaq: GCL) (“GCL” or the “Company”), a leading provider of games and entertainment, today provided an update on management’s expectations for financial results for the fiscal year 2026, ending March 31, 2026. The Company’s anticipated results reflect its continued growth trajectory in the core consumer and gaming-adjacent verticals, underpinned by the integration of Ban Leong Technologies, including its established distribution footprin ...

Core Insights - Nightfood Holdings Inc. has reported a significant increase in temporary equity of approximately $91.5 million, attributed to strategic hotel acquisitions aimed at enhancing its AI-driven robotics model [3] - The company is positioning itself as a leader in the hospitality sector by integrating artificial intelligence and robotics, which is expected to improve operational efficiency and reduce costs [4] - The global service robotics market is projected to exceed $170 billion by 2030, providing a substantial growth opportunity for Nightfood Holdings [4] Company Overview - Nightfood Holdings Inc. is focused on revolutionizing the hospitality industry through AI-powered robotics and strategic hotel acquisitions [4] - The company's business model includes owning hotel properties and offering Robotics-as-a-Service (RaaS), which allows for scalable revenue streams [4] - The recent quarterly results indicate a strong financial position that supports the company's goal of uplisting and further development as a data-centric hospitality automation platform [3] Industry Context - Investors are increasingly prioritizing companies that can demonstrate credible and measurable earnings improvement, particularly in fast-growing sectors like artificial intelligence and service robotics [2] - The hospitality industry is experiencing a shift towards automation, with companies like Nightfood leading the way in setting new operational standards [4]

Core Insights - Worksport Ltd. has launched its new HD3 heavy-duty tonneau cover, which is now available through its expanding B2B dealer network, with production having started in mid-October [1][2][3] - The HD3 cover is priced starting at $869 and is designed for durability and protection, targeting commercial and high-use customers [2][4] - The company plans to focus on dealer sales for the HD3, while also preparing for direct-to-consumer sales in December [3][4] - Worksport's clean-tech products, COR and SOLIS, will open for initial orders on November 28, representing a new revenue stream for the company [5][6] - The company emphasizes that the HD3, SOLIS, and COR products are the result of years of engineering investment and are expected to drive revenue growth and market presence [7][8] Product Details - The HD3 tonneau cover features upgraded materials, reinforced seals, and heavy-duty latching systems, enhancing its ruggedness compared to previous models [2][4] - SOLIS is a solar-integrated truck bed system designed for renewable power applications, while COR is a modular energy storage system for various utility needs [7][8] Strategic Focus - The introduction of the HD3 is seen as a strategic move to enhance Worksport's product offerings in both B2B and B2C channels, aiming for unit sales growth and channel diversification [4][6] - The company is committed to advancing its manufacturing capabilities and expanding its product portfolio in clean energy and automotive accessories [8]

Core Insights - PolyPid Ltd. is participating in a virtual Key Opinion Leader event to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX100 [1][2] Company Overview - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through locally administered, controlled, prolonged-release therapeutics [6] - The company utilizes proprietary PLEX technology to enable precise drug delivery at optimal release rates over durations from several days to months [6] Product Information - D-PLEX100 is PolyPid's lead product candidate designed to provide local prolonged and controlled antibacterial activity at the surgical site to prevent surgical site infections (SSIs) [5] - D-PLEX100 demonstrated a statistically significant 58% relative risk reduction in SSI incidence following abdominal colorectal surgery in the Phase 3 SHIELD II trial [5] - The product received Breakthrough Therapy designation from the U.S. FDA for the prevention of SSIs in elective colorectal surgery [5] Upcoming Events - The KOL event titled "The Science and Business Case for D-PLEX100" is scheduled for December 10, 2025, featuring Dr. Steven D. Wexner discussing SSIs and D-PLEX100's role in addressing this unmet medical need [2][3] Future Plans - PolyPid plans to submit a New Drug Application (NDA) for D-PLEX100 in early 2026 following positive Phase 3 results [7] - The company is also developing an innovative pipeline in oncology, obesity, and diabetes [7]